Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

  1. Herraez, E.
  2. Lozano, E.
  3. Macias, R.I.R.
  4. Vaquero, J.
  5. Bujanda, L.
  6. Banales, J.M.
  7. Marin, J.J.G.
  8. Briz, O.
Journal:
Hepatology

ISSN: 0270-9139 1527-3350

Year of publication: 2013

Volume: 58

Issue: 3

Pages: 1065-1073

Type: Article

DOI: 10.1002/HEP.26425 GOOGLE SCHOLAR

Sustainable development goals